Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive.

Saved in:

Bibliographic Details
Title:	Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive.
Authors:	Fitz-Patrick, David¹ (AUTHOR), Sahgal, Omair² (AUTHOR), Fouché, Leon F.³ (AUTHOR), Mitha, Essack⁴ (AUTHOR), Malahleha, Mookho⁵ (AUTHOR), Gayed, Juleen² (AUTHOR) juleen.gayed@pfizer.com, Keep, Georgina² (AUTHOR), Zhang, Ying⁶ (AUTHOR), Modjarrad, Kayvon⁶ (AUTHOR), Belanger, Todd⁶ (AUTHOR), Xu, Xia⁶ (AUTHOR), Cooper, David⁶ (AUTHOR), Mensa, Federico J.⁷ (AUTHOR), Sahin, Uǧur⁷ (AUTHOR), Türeci, Ӧzlem⁷ (AUTHOR), Swanson, Kena A.⁶ (AUTHOR), Anderson, Annaliesa S.⁶ (AUTHOR), Gurtman, Alejandra⁶ (AUTHOR), Kitchin, Nicholas² (AUTHOR)
Source:	Infectious Diseases & Therapy. Jul2026, p1-23. 23p.
Database:	Academic Search Ultimate

Description
ISSN:	21938229
DOI:	10.1007/s40121-026-01409-1